Compare GGT & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GGT | SCLX |
|---|---|---|
| Founded | 1994 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.8M | 139.3M |
| IPO Year | N/A | N/A |
| Metric | GGT | SCLX |
|---|---|---|
| Price | $4.20 | $16.48 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 59.7K | ★ 121.9K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $40,360,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $749.70 |
| P/E Ratio | $6.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.32 | $3.60 |
| 52 Week High | $7.00 | $34.27 |
| Indicator | GGT | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 41.66 |
| Support Level | $4.16 | $18.34 |
| Resistance Level | $4.32 | $20.62 |
| Average True Range (ATR) | 0.05 | 1.46 |
| MACD | 0.02 | -0.39 |
| Stochastic Oscillator | 59.09 | 3.10 |
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.